Cronos Group Q3 revenue misses expectations

Cronos

06/11/2025 12:41

Overview

Cronos Q3 revenue of $36.3 mln missed analyst expectations

Adjusted EBITDA of $5.7 mln in Q3 beat analyst estimates

Company achieved record net revenue in Israel, driven by PEACE NATURALS brand

Outlook

Cronos expects Cronos GrowCo expansion to fuel growth in 2026

Company anticipates international revenue alignment in second-half 2025

Cronos plans to continue expanding globally and investing in innovation

Result Drivers

ISRAEL PERFORMANCE - Record net revenue in Israel driven by PEACE NATURALS brand, maintaining its position as the leading cannabis brand in the country

CANADIAN MARKET - Increased cannabis extract sales in Canada, although flower sales were constrained, contributing to revenue growth

COST DISCIPLINE - Improved gross profit due to lower inventory step-up costs and strategic sales mix shift to higher-margin regions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$36.30 mln
$37.30 mln (1 Analyst)
Q3 Net Income
$28.30 mln
Q3 Adjusted EBITDA
Beat
$5.70 mln
$5.60 mln (1 Analyst)
Q3 Gross Profit
$18.30 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 93 three months ago

Press Release: ID:nGNX6qFvvh

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)